GLIVEC RECEIVES POSITIVE EUROPEAN UNION OPINION FOR TREATMENT OF RARE, POTENTIALLY LIFE-THREATENING CANCERS WITH LIMITED TREATMENT OPTIONS

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion for the use of Glivec (imatinib)[1] as a treatment for the solid tumor dermatofibrosarcoma protuberans (DFSP) and for hematologic malignancy Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL).

MBL.is (http://www.mbl.is/mm/vidskipti/hugin_news.html?id=1066400)